Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords "fibromyalgia'', "treatment or management'' and "trial''. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and "other pharmacological'' and exercise, cognitive behavioural therapy, education, dietary interventions and "other non-pharmacological''. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.
Original languageEnglish
Pages (from-to)93-99
JournalArchives of Biochemistry and Biophysics
Volume475
Issue number2
DOIs
Publication statusPublished - 15 Jul 2008

Fingerprint

Antley-Bixler Syndrome Phenotype
Cytochrome P-450 CYP1A2
Fibromyalgia
Xenobiotics
Metabolism
Cytochrome P-450 Enzyme System
Oxidoreductases
Chronic Fatigue Syndrome
Outcome Assessment (Health Care)
Pharmacology
Antidepressive Agents
Analgesics
Cognitive Therapy
Advisory Committees
Pain Measurement
Random Allocation
Education
Fatigue of materials
Sample Size
Consensus

Cite this

@article{6c5c9ed554374835b7719b6f36333e04,
title = "Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase",
abstract = "Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords {"}fibromyalgia'', {"}treatment or management'' and {"}trial''. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and {"}other pharmacological'' and exercise, cognitive behavioural therapy, education, dietary interventions and {"}other non-pharmacological''. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.",
keywords = "ESCHERICHIA-COLI MTC, BIOACTIVATION ACTIVITIES, STIMULATORY ROLE, DISORDERED STEROIDOGENESIS, polymorphism, NADPH-FLAVODOXIN REDUCTASE, NADPH-cytochrome P450 oxidoreductase, adverse drug reactions, Antley-Bixler syndrome, cytochrome P450, CYP1A2, drug-metabolizing enzymes, GENETIC-VARIATION, P450 1A2, MUTAGENICITY TESTER STRAIN, protein-protein interaction, MUTANT P450 OXIDOREDUCTASE, HUMAN CYP1A2, POR, CELL EXPRESSION SYSTEM",
author = "Michel Kranendonk and Duarte, {Maria Paula Amaro de Castilho} and J. Rueff",
year = "2008",
month = "7",
day = "15",
doi = "10.1016/j.abb.2008.04.014",
language = "English",
volume = "475",
pages = "93--99",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "ELSEVIER SCIENCE INC",
number = "2",

}

TY - JOUR

T1 - Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase

AU - Kranendonk, Michel

AU - Duarte, Maria Paula Amaro de Castilho

AU - Rueff, J.

PY - 2008/7/15

Y1 - 2008/7/15

N2 - Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords "fibromyalgia'', "treatment or management'' and "trial''. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and "other pharmacological'' and exercise, cognitive behavioural therapy, education, dietary interventions and "other non-pharmacological''. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.

AB - Objective: To develop evidence-based recommendations for the management of fibromyalgia syndrome. Methods: A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords "fibromyalgia'', "treatment or management'' and "trial''. Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation. Results: 146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and "other pharmacological'' and exercise, cognitive behavioural therapy, education, dietary interventions and "other non-pharmacological''. In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made. Conclusions: Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.

KW - ESCHERICHIA-COLI MTC

KW - BIOACTIVATION ACTIVITIES

KW - STIMULATORY ROLE

KW - DISORDERED STEROIDOGENESIS

KW - polymorphism

KW - NADPH-FLAVODOXIN REDUCTASE

KW - NADPH-cytochrome P450 oxidoreductase

KW - adverse drug reactions

KW - Antley-Bixler syndrome

KW - cytochrome P450

KW - CYP1A2

KW - drug-metabolizing enzymes

KW - GENETIC-VARIATION

KW - P450 1A2

KW - MUTAGENICITY TESTER STRAIN

KW - protein-protein interaction

KW - MUTANT P450 OXIDOREDUCTASE

KW - HUMAN CYP1A2

KW - POR

KW - CELL EXPRESSION SYSTEM

U2 - 10.1016/j.abb.2008.04.014

DO - 10.1016/j.abb.2008.04.014

M3 - Article

VL - 475

SP - 93

EP - 99

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

IS - 2

ER -